Cargando…
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is the only available biomarker that can guide treatment with immune checkpoint inhibitor...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Society of Pathologists and the Korean Society for Cytopathology
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639705/ https://www.ncbi.nlm.nih.gov/pubmed/31042863 http://dx.doi.org/10.4132/jptm.2019.04.24 |